Madrigal Pharmaceuticals (MDGL)

• Market cap: $11.9B
• 1 day: -0.89%
• 5 days: -3.48%
• 1 month: 20.06%
• 3 months: 1.78%
• 6 months: 20.95%
• Year to date: -12.5%
• 1 year: 69.06%
• 5 years: 344.04%
• 10 years: 6,160.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Employees: 915